Meeting
2023 ASCO Annual Meeting
MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Authors
Cyrille Touzeau
Centre Hospitalier Universitaire de Nantes, Nantes, France
Cyrille Touzeau , Vania TM Hungria , Divaya Bhutani , Ola Landgren , Diego Vieyra , Yue Guo , Raluca Verona , Xin Miao , Mia Qi , Latisha Watkins , Priya Shah , Katherine Chastain , Ming Qi , HANG QUACH
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05572515
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8067)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8067
Abstract #
TPS8067
Poster Bd #
57a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).
First Author: Paul Gerard Guy Richardson
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto